Regulatory
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Navigate global pharma regulatory landscapes. Get critical intelligence on FDA, EMA, and global drug approval pathways for strategic decision-making.
Showing 1–12 of 24 articles
Abivax colitis drug hits goal, but cancer cases rattle investors
Abivax's obefazimod met primary efficacy endpoints in a late-stage ulcerative colitis trial, but three cancer cases among treated patients sent shares down 27%. The safety signal, deemed unrelated by investigators, creates uncertainty for regulatory filings and partnership discussions.
STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS
President Trump's executive order reclassifying thousands of federal workers under Schedule F removes civil service protections for senior HHS staff, including at FDA, NIH, and CDC. This analysis explains the policy change, its implications for pharmaceutical regulatory processes, and what BD teams should monitor next.
Aurobindo Pharma OAI Classification: Implications for Drug Approvals
The FDA has classified a subsidiary unit of Aurobindo Pharma as Official Action Indicated (OAI), signaling significant regulatory non-compliance. This status threatens pending drug approvals and reshapes the competitive landscape for generic and specialty pharmaceuticals.
Lee, Tuberville Introduce Protections for Homeopathic Medicine with FDA Approval Framework
U.S. Senators Mike Lee and Tommy Tuberville introduced legislation on June 5, 2026, to create an FDA framework for homeopathic medicine. The Homeopathic Drug Product Safety, Quality, and Transparency Act provides a regulatory pathway for homeopathic products without requiring them to fit traditional pharmaceutical categories.
OHRP Underfunding Risks Human Subject Protection in 2026
The Office for Human Research Protections (OHRP) is now operating with only a fraction of its mandated staff, creating risks for oversight of human subject safety under The Federal regulations at 45 CFR 46. Pharma strategy and BD teams should prepare for potential delays in regulatory guidance and increased reliance on institutional IRBs.
Texas AG Investigating Energy Drinks: What Pharma Teams Need to Know
Texas Attorney General Ken Paxton has launched an investigation into Celsius Holdings over marketing practices and caffeine levels in its energy drinks. This article breaks down the development, its implications for pharma and beverage companies, and key questions for industry teams.
Top 10 Pharmaceutical Stocks to Buy for June 2026: A B2B Analysis
This analysis identifies the top 10 pharmaceutical stocks to buy for June 2026, focusing on catalysts, sales growth, and regulatory tailwinds from the EMA. It provides actionable insights for BD teams, investors, and analysts seeking high-upside opportunities.
AI Titans Push Congress for DNA Safeguards: Implications for Biotech Strategy
OpenAI, Anthropic, Inceptive Nucleics, and Grail are urging Congress to enact DNA safeguards, signaling a shift in the regulatory landscape for genomic data. This article analyzes the competitive and strategic implications for biotech firms.
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means — drug approvals
HHS Secretary Robert F. Kennedy Jr. announced the FDA will reclassify approximately 14 peptides from Category 2 (restricted) to Category 1 (allowable) for compounding pharmacies. This shift, based on the claim that original restrictions lacked legitimate safety signals, opens new market access for unproven peptides and signals a regulatory pivot with significant implications for pharma BD teams and investors.
Bio-IT World Conference 2026: Live Event Coverage
Live coverage of the Bio-IT World Conference 2026 in Boston, highlighting key announcements, partnership trends, and regulatory implications for pharma BD and strategy teams.
Kenya Court Halts U.S. Ebola Quarantine Facility Plans: Pharma Sector Analysis
A Kenyan High Court has suspended a U.S. plan to build an Ebola quarantine facility for Americans, raising new risks for pharma companies operating in Africa. The decision highlights the need for stronger local regulatory engagement and community-focused access strategies.
Drug Discovery USA 2026: What to Expect
Drug Discovery USA 2026 in Cambridge, MA, will spotlight breakthrough drug launches and regulatory updates. This analysis covers key takeaways, implications for pharma teams, and answers to top industry questions.